The Stanley Foundation Bipolar Network
| Autor: | Mark A. Frye, K. D. Denicoff, Willem A. Nolen, Paul E. Keck, R. M. Post, Gabriele S. Leverich, A. J. Rush, Ralph Kupka, Trisha Suppes, L. L. Altshuler, Susan L. McElroy |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Olanzapine
medicine.medical_specialty medicine.drug_class business.industry Mood stabilizer Lamotrigine medicine.disease Mental health Antimanic Agents 030227 psychiatry Treatment of bipolar disorder Clinical trial 03 medical and health sciences Psychiatry and Mental health 0302 clinical medicine medicine 030212 general & internal medicine Bipolar disorder Psychiatry business medicine.drug |
| Zdroj: | British Journal of Psychiatry. 178:s177-s183 |
| ISSN: | 1472-1465 0007-1250 |
| DOI: | 10.1192/bjp.178.41.s177 |
| Popis: | Background The Stanley Foundation Bipolar Network (SFBN) evaluates treatments, course and clinical and neurobiological markers of response in bipolar illness. Aims To give a preliminary summary of emerging findings in these areas. Method Studies with established and potentially antimanic, antidepressant and mood-stabilising agents range from open case series to double-blind randomised clinical trials, and use the same core assessment methodology, thereby optimising the comparability of the outcomes. The National Institute of Mental Health Life Chart Method is the core instrument for retrospective and prospective longitudinal illness description. Results The first groups of patients enrolled show a considerable degree of past and present symptomatology, psychiatric comorbidity and functional impairment. There are associations of both genetic and early environmental factors with more severe courses of illness. Open case series with add-on olanzapine, lamotrigine, gabapentin or topiramate show a differential spectrum of effectiveness in refractory patients. Conclusions The SFBN provides important new data for the understanding and treatment of bipolar disorder. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|